<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Bright Minds Biosciences Inc — News on 6ix</title>
    <link>https://6ix.com/company/bright-minds-biosciences-inc</link>
    <description>Latest news and press releases for Bright Minds Biosciences Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 09 Jan 2026 16:56:05 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/bright-minds-biosciences-inc" rel="self" type="application/rss+xml" />
    <item>
      <title>Bright Minds Biosciences Announces Closing of US$175 Million Public Offering</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-closing-of-usdollar175-million-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-closing-of-usdollar175-million-public-offering</guid>
      <pubDate>Fri, 09 Jan 2026 16:56:05 GMT</pubDate>
      <description>NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) --  Bright   Minds Biosciences Inc. (CSE: DRUG) (NASDAQ:...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-pricing-023300741</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-pricing-023300741</guid>
      <pubDate>Thu, 08 Jan 2026 02:33:00 GMT</pubDate>
      <description>NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the pricing of its previously announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of $90.00 per Common Share for anticipated gross proceeds of $175,050,000 (the “Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additi</description>
    </item>
    <item>
      <title>Bright Minds Biosciences Announces Launch of US$100 Million Public Offering</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-launch-of-usdollar100-million-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-launch-of-usdollar100-million-public-offering</guid>
      <pubDate>Tue, 06 Jan 2026 21:00:00 GMT</pubDate>
      <description>NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) --  Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: D...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-positive-topline-results-from-phase-2-clinical-trial-of-bmb-101-in-patients-with-absence-seizures-and-developmental-and-encephalopathic-epilepsies-dee</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-positive-topline-results-from-phase-2-clinical-trial-of-bmb-101-in-patients-with-absence-seizures-and-developmental-and-encephalopathic-epilepsies-dee</guid>
      <pubDate>Tue, 06 Jan 2026 12:16:55 GMT</pubDate>
      <description>BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and t...</description>
    </item>
    <item>
      <title>Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-to-announce-topline-results-for-bmb-101-phase-2-trial-in-absence-seizures-and-developmental-and-epileptic-encephalopathies-on-tuesday-january-6-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-to-announce-topline-results-for-bmb-101-phase-2-trial-in-absence-seizures-and-developmental-and-epileptic-encephalopathies-on-tuesday-january-6-2026</guid>
      <pubDate>Mon, 05 Jan 2026 21:30:00 GMT</pubDate>
      <description>&amp;#x2013; Conference Call and Live Webcast at 8AM ET &amp;#x2013;    NEW YORK, Jan. 05, 2026 (GLOBE NE...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-to-present-at-piper-sandler-37th-annual-healthcare-conference-and-2025-aes-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-to-present-at-piper-sandler-37th-annual-healthcare-conference-and-2025-aes-annual-meeting</guid>
      <pubDate>Tue, 25 Nov 2025 21:30:00 GMT</pubDate>
      <description>NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (&amp;#x201C;Bright Minds,...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-expands-scientific-advisory-board-to-include-renowned-experts-in-prader-willi-syndrome-pws</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-expands-scientific-advisory-board-to-include-renowned-experts-in-prader-willi-syndrome-pws</guid>
      <pubDate>Mon, 17 Nov 2025 11:50:00 GMT</pubDate>
      <description>-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and There...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-initiates-new-prader-willi-syndrome-pws-program-kol-event-scheduled-for-november-6th</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-initiates-new-prader-willi-syndrome-pws-program-kol-event-scheduled-for-november-6th</guid>
      <pubDate>Thu, 06 Nov 2025 11:30:00 GMT</pubDate>
      <description>-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to a...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences to&amp;#xA0;Present at Upcoming Conferences</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-toandxa0present-at-upcoming-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-toandxa0present-at-upcoming-conferences</guid>
      <pubDate>Thu, 30 Oct 2025 22:30:00 GMT</pubDate>
      <description>NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (&amp;#x201C;Bright Minds,...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences to Present at Upcoming Conferences</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-present-upcoming-223000273</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-present-upcoming-223000273</guid>
      <pubDate>Thu, 30 Oct 2025 22:30:00 GMT</pubDate>
      <description>NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT:Guggenheim 2nd Annual Healthcare Innovation Conference DATE:Wednesday, November 12, 2025 TIME:</description>
    </item>
    <item>
      <title>BRIGHT MINDS BIOSCIENCES ANNOUNCES AT-THE-MARKET OFFERING</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-at-the-market-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-at-the-market-offering</guid>
      <pubDate>Fri, 05 Sep 2025 00:00:00 GMT</pubDate>
      <description>BRIGHT MINDS BIOSCIENCES ANNOUNCES AT-THE-MARKET OFFERING           Canada NewsWire             V...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences Announces BMB?201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-bmb201-outperforms-sumatriptan-in-validated-preclinical-vascular-headache-model</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-bmb201-outperforms-sumatriptan-in-validated-preclinical-vascular-headache-model</guid>
      <pubDate>Thu, 04 Sep 2025 12:30:00 GMT</pubDate>
      <description>NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG) today a...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-bmb-123000685</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-bmb-123000685</guid>
      <pubDate>Thu, 04 Sep 2025 12:30:00 GMT</pubDate>
      <description>NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG) today announced compelling preclinical results for its investigational compound BMB‑201, in a validated isosorbide dinitrate (ISDN) rat model of vascular headache. BMB-201 produced statistically significant reductions in facial mechanical allodynia across both male and female cohorts at 1 and 2 hours post-dose, compared to vehicle, and demonstrated greater effect sizes than sumatriptan at multiple timepoint</description>
    </item>
    <item>
      <title>Bright Minds Biosciences to Present at Upcoming Conferences</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-to-present-at-upcoming-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-to-present-at-upcoming-conferences</guid>
      <pubDate>Mon, 25 Aug 2025 12:00:00 GMT</pubDate>
      <description>NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (&amp;#x201C;Bright Minds,...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-to-present-at-the-2025-jefferies-global-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-to-present-at-the-2025-jefferies-global-healthcare-conference</guid>
      <pubDate>Wed, 28 May 2025 12:00:00 GMT</pubDate>
      <description>NEW YORK and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Bioscienc...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&amp;D Day on May 20, 2025</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-featured-speakers-for-its-absence-epilepsy-virtual-randd-day-on-may-20-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-featured-speakers-for-its-absence-epilepsy-virtual-randd-day-on-may-20-2025</guid>
      <pubDate>Tue, 20 May 2025 12:00:00 GMT</pubDate>
      <description>- Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D&amp;#x2019;Souza...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-positive-findings-from-its-dba2-mouse-model-study-evaluating-bmb-101</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-announces-positive-findings-from-its-dba2-mouse-model-study-evaluating-bmb-101</guid>
      <pubDate>Tue, 13 May 2025 12:30:00 GMT</pubDate>
      <description>- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model -     - Th...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences to Host Virtual R&amp;D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-to-host-virtual-randd-day-on-may-20-2025-program-highlights-include-an-overview-of-absence-seizures-and-the-bmb-101-phase-2-study</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-to-host-virtual-randd-day-on-may-20-2025-program-highlights-include-an-overview-of-absence-seizures-and-the-bmb-101-phase-2-study</guid>
      <pubDate>Mon, 28 Apr 2025 12:00:00 GMT</pubDate>
      <description>VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CS...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-expands-scientific-advisory-board-to-include-renowned-leaders-in-epilepsy-research</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-expands-scientific-advisory-board-to-include-renowned-leaders-in-epilepsy-research</guid>
      <pubDate>Tue, 04 Mar 2025 13:00:00 GMT</pubDate>
      <description>&amp;#x2013;&amp;#xA0;Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O&apos;Brien, MD; Jo Sourbron, ...</description>
    </item>
    <item>
      <title>Bright Minds Biosciences to Participate at Three Healthcare Conferences in March</title>
      <link>https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-to-participate-at-three-healthcare-conferences-in-march</link>
      <guid isPermaLink="true">https://6ix.com/company/bright-minds-biosciences-inc/news/bright-minds-biosciences-to-participate-at-three-healthcare-conferences-in-march</guid>
      <pubDate>Mon, 24 Feb 2025 11:50:00 GMT</pubDate>
      <description>NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Bioscien...</description>
    </item>
  </channel>
</rss>